

SPINE SAFETY CAUTIONARY NOTICE:

**Information for Healthcare Professionals:  
Drug Safety Labeling Changes -  
Rozerem (ramelteon) Tablets**

According to MedWatch, FDA notified healthcare professionals that the PRECAUTIONS text for Rozerem (ramelteon) Tablets has been updated. The following sentences have been added to the labeling:

**PRECAUTION**

***Drug Interactions***

- Donepezil increases systemic exposure of ramelteon; patients should be closely monitored when ramelteon is co administered with donepezil.
- Doxepin increases systemic exposure of ramelteon; patients should be closely monitored when ramelteon is co administered with doxepin.

Read the complete summary of MedWatch safety labeling changes at:

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm233843.htm>

The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a variety of government and other resources for patient safety related notices that may be useful to our members. Information from these notices is also archived on the NASS website at <http://www.spine.org/Pages/PracticePolicy/ClinicalCare/SpineSafetyAlerts/Default.aspx>.

This information is provided as a service for information and education only.